郝华-医学院

师资与博后

导师信息当前所在位置：首页 >> 师资与博后 >> 研究生导师 >> 导师信息

	郝华副主任医师，副教授
	硕士招生类型：学术型硕士招生专业：临床检验诊断学博士招生类型：专业型博士招生专业：临床检验诊断学
	所在院系：附属杨浦医院
	联系方式：haohua410@tongji.edu.cn
	课题组链接：

研究方向主要任职科研业绩炎症与肿瘤的发生机制，尤其是肿瘤免疫微环境研究。 The mechanisms underlying inflammation and tumorigenesis, particularly research on the tumor immune microenvironment. 同济大学附属杨浦医院病理科副主任（主持工作），病理科学科带头人，同济大学副教授，上海市医学会病理专科分会委员，上海市医师协会病理科医师分会委员，杨浦区病理质控组组长。华中科技大学同济医学院病理学与病理生理学专业博士毕业。 Director of Department of Pathology, Yangpu Hospital, School of Medicine, Tongji University, Acatemic Leader of Pathology Department, Associate Professor of Tongji University, committee member of Pathology sub-committee of Shanghai Medical Association, committee member of the Pathologists Branch of Shanghai Physicians Association and the head of Yangpu District Pathology Quality Control Group. D. degree in Pathology and Pathophysiology from Tongji Medical College, Huazhong University of Science and Technology. Advanced Science、Cancer Letters、International Journal of Biological Sciences、Journal of Translational Medicine、Journal of Leukocyte Biology、International Immunopharmacology、Therapeutic Advances in Medical Oncology、Cellular Signalling、Cancer Medicine、Experimental Cell Research、European Journal of Medical Research、Journal of Cosmetic Dermatology、Acta Histochemica、Renal Failure等杂志审稿专家，主持国家自然科学基金1项，省部级课题5项，市局级课题4项，区级课题1项。发表一作（含共一）及通讯作者SCI论文27篇（最高IF15.7）。近4年发表SCI论文： 1.Cheng J, Zheng J, Ma C, Li Y, Hao H* (通讯作者). T-Cell Senescence: Unlocking the Tumor Immune “Dark Box” - A Multidimensional Analysis from Mechanism to Tumor Immunotherapeutic Intervention. Seminars in Cancer Biology, 2025, 113:190-209. (IF 15.7). 2. Zhou B, Zhao Q, Li X, Liu H, Hao H* (通讯作者). Small intestinal NK/T-cell lymphoma with malignant peritoneal effusion as the first symptom: a case report and literature review. Frontiers in Medicine,2025, 12:1610820. 3. Yan L, Zhang J, Zheng J, Hao H* (通讯作者). Biomarkers in spinal muscular atrophy. Frontiers in Neurology, 2025, 16:1636992. 4.Feng Y, Qu X, Hao H* (通讯作者). Progress in the study of the effects of selective serotonin reuptake inhibitors (SSRIs) on the reproductive system. Frontiers in Pharmacology, 2025, 16:1567863. 5.Zhou B, Zheng J, Huang L, Hao H* (通讯作者). Esophageal submucosal gland duct adenoma: a case report and literature review. Frontiers in Oncology, 2025, 15:1525781. 6.Zheng J, Xu F, Li G, Lin M, Hao H* (通讯作者). The value of chromosome instability detected by low-pass whole-genome sequencing in preoperative prediction of sentinel lymphnode metastasis in breast cancer. Frontiers in Oncology, 2024, 14:1434526. 7.Zheng J, Hao H* (通讯作者). Targeting Renal Damage: The ACE2/Ang-(1–7)/Mas Axis in Chronic Kidney Disease. Cellular Signalling, 2024,124:111413. 8.Zheng J, Hao H* (通讯作者). The importance of cancer-associated fibroblasts in targeted therapies and drug resistance in breast cancer. Frontiers in Oncology, 2024, 13:1333839. 9.Zhou B, Guo M, Li X, Duan T, Peng L, Hao H* (通讯作者). Clinicopathological and molecular genetic alterations in monomorphic-epitheliotropic intestinal T-cell lymphoma of the small intestine. European Journal of Medical Research, 2024,29(1):191. 10.Zhou B, Gan X, Li X, Peng L, Hao H* (通讯作者). Ureter mixed neuroendocrine-non-neuroendocrine neoplasm: a case report and literature review. Frontiers in Oncology, 2024,14:1390350. 11.Wang Y, He Z, Hao H* (通讯作者). A case report of primary Kaposiform hemangioendothelioma of the humerus. International Journal of Immunopathology and Pharmacology, 2024:3946320241266914. 12.Yan L, Zheng J, Wang Q, Hao H* (通讯作者). Role of cancer-associated fibroblasts in colorectal cancer and their potential as therapeutic targets. Biochemical and Biophysical Research Communications, 2023, 681:127-135. 13.Zheng J, Tang C, Liu P, Hao H* (通讯作者). Carcinosarcoma of the ovary: a case report andliterature review. Frontiers in Oncology, 2023,13:1278300. 14. Xu F, Zhou X, Lin L, Xu J, Feng Y, He Y, Hao H* (通讯作者). BML-111, the agonist of lipoxin A4, suppresses epithelial-mesenchymal transition and migration of MCF-7 cells via regulating the lipoxygenase pathway. International Journal of Immunopathology and Pharmacology, 2023,37:3946320231223826. 15. Hao H, Xie F, Xu F, Wang Q, Wu Y, Zhang D. LipoxinA4 analog BML-111 protects podocytes cultured in high-glucose medium against oxidative injury via activating Nrf2 pathway. International Immunopharmacology, 2022, 111:109170. 16. Zhang J, Zhou X, Hao H* (通讯作者). Macrophage phenotype-switching in cancer. EuropeanJournal of Pharmacology, 2022, 931:175229. 17. Xu F, Zhang J, Zhou X, Hao H* (通讯作者). Lipoxin A4 and its analog attenuate high fatdiet-induced atherosclerosis via Keap1/Nrf2 pathway. Experimental Cell Research, 2022, 412:113025.